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Summary 
Background: After no research in humans for more than 40 years, there is renewed interest 
in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There 
are no modern studies on the subjective and autonomic effects of LSD and its endocrine 
effects are unknown. LSD disrupts prepulse inhibition (PPI) of the acoustic startle response in 
animals, and schizophrenia patients exhibit similar impairments in PPI. However, no data are 
available on the effects of LSD on PPI in humans. 
Methods: LSD (200µg) and placebo were administered to 16 healthy subjects (eight women, 
eight men) in a double-blind, randomized, placebo-controlled, cross-over study. The outcome 
measures included psychometric scales, investigator ratings, PPI of the acoustic startle 
response, autonomic, endocrine, and adverse effects.  
Results: LSD produced pronounced alterations in waking consciousness that lasted 12h. LSD 
predominantly induced visual hallucinations, audio-visual synesthesia, and positively 
experienced derealization and depersonalization phenomena. LSD also increased subjective 
well-being, happiness, closeness to others, openness, and trust. LSD decreased PPI 
compared with placebo. LSD significantly increased blood pressure, heart rate, body 
temperature, pupil size, plasma cortisol, prolactin, oxytocin, and epinephrine. LSD produced 
adverse effects which completely subsided within 72h. No severe acute adverse effects were 
observed. 
Conclusions: In addition to marked hallucinogenic effects, LSD exerts MDMA-like 
empathogenic mood effects that may be useful in psychotherapy. LSD altered sensorimotor 
gating in a human model of psychosis, supporting the use of LSD in translational psychiatric 
research. LSD can safely be used in a controlled clinical setting but produces significant 
sympathomimetic stimulation. 
 
Trial registration: clinicaltrials.gov Identifier: NCT01878942 
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Introduction 
 Lysergic acid diethylamide (LSD) is a prototypical classic hallucinogen (1, 2). The 
psychotropic effects of LSD were discovered in 1943 by Albert Hofmann in Basel (3). In the 
1950s to 1970s, LSD was initially used as an experimental tool (“psychotomimetic”) to study 
psychotic-like states and model psychosis (4, 5) and as an adjunct in “psycholytic 
psychotherapy.” LSD has also been investigated for the treatment of alcoholism (6), addiction 
(7), cluster headache (8), and anxiety associated with terminal illness (9-11). Today, LSD is 
illicitly used for recreational (personal or spiritual) purposes. The lifetime prevalence of LSD 
use among adults is in the range of 6-8% (12, 13). Despite LSD’s widespread recreational use, 
no scientific pharmacological studies have been conducted with LSD in the last 40 years. After 
the initial psychiatric investigation by Stoll (14), several case reports and studies in the 1950s 
and 1960s described aspects of the psychological effects of LSD (5, 15-17). However, these 
studies were not performed according to today’s research standards and did not include 
control conditions or the systematic characterization of psychotropic effects. Many studies also 
sought to describe the psychotomimetic effects of LSD but were not designed to measure any 
positive subjective effects. Modern experimental studies with hallucinogens in humans 
resumed in the 1990s with N-N-dimethyltryptamine (DMT, ayahuasca) (18-21), ketamine (21-
23), and psilocybin (24, 25) but not with LSD. Both LSD and psilocybin have also been 
recently evaluated in pilot therapeutic studies as treatments for anxiety in patients with life-
threatening diseases (11, 26). Because of the continued popularity of LSD as a recreational 
drug and renewed interest in its therapeutic use (11, 27), we reexamined the acute response 
to LSD in healthy subjects. To allow for a better characterization of the subjective effects of 
LSD, we used psychometric instruments that have been used with other psychotropic drugs, 
including hallucinogens, empathogens, and stimulants (20, 21, 28-31).  
Serotonergic hallucinogens, including psilocybin, DMT, and LSD, elicit mostly visual 
perceptual disturbances that are partially similar to those observed in early schizophrenia (21, 
32-34). Hallucinogens also induce alterations in information processing that are similar to 
those observed in schizophrenia. Specifically, prepulse inhibition (PPI) of the acoustic startle 
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response serves as an operational measure of sensorimotor gating that can be assessed in 
animals and humans (35). PPI is impaired in schizophrenia and also in prodromal states and 
early phases (35-38), and hallucinogens like LSD acutely disrupt PPI in animals (39-44). 
Prepulse inhibition in animals, therefore, serves as a preclinical model of schizophrenia (45). 
However, the effects of LSD on sensorimotor gating function have not yet been explored in 
humans and therefore were tested in the present study. We hypothesized that LSD would 
produce alterations in waking consciousness and impair PPI. Additionally, no data are 
available on the acute autonomic and adverse effects of LSD and the endocrine effects of LSD 
in humans are unknown. Thus, up-to-date clinical safety data are mostly missing. Because of 
the continued popularity of LSD as a recreational drug and interest in its therapeutic use, we 
also examined the acute somatic and endocrine response to LSD. 
 
Material and Methods 
 
Participants 
Sixteen healthy subjects (eight men and eight women; mean age±SD: 28.6±6.2 years; range: 
25-51 years) were recruited by word of mouth or an advertisement placed on the web market 
platform of the University of Basel. All of the subjects provided written informed consent and 
were paid for their participation. Additionally, we considered the safety recommendations for 
high-dose hallucinogen research (46, 47). The participant characteristics are described in 
detail in Supplement 1. Seven subjects had used a hallucinogen 1-3 times and another four 
subjects had prior experience with MDMA (2-4 times).  
 
Study design 
 The study used a double-blind, placebo-controlled, cross-over design with two 
experimental test sessions in balanced order. The washout periods between sessions were at 
least 7 days. The study was conducted in accordance with the Declaration of Helsinki and 
International Conference on Harmonization Guidelines in Good Clinical Practice (ICH-GCP) 
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and approved by the Ethics Committee of the Canton of Basel, Switzerland, and Swiss Agency 
for Therapeutic Products (Swissmedic). The administration of LSD to healthy subjects was 
authorized by the Swiss Federal Office for Public Health, Bern, Switzerland. The study was 
registered at ClinicalTrials.gov (NCT01878942).  
 
Drugs 
 LSD was administered in a single absolute dose of 200µg, corresponding to a dose of 
2.84±0.13µg/kg body weight (mean±SEM; range, 2.04-3.85µg). The same dose was used in 
LSD-assisted psychotherapy in a clinical study (11). The dose was within the range of doses 
taken for recreational purposes and expected to induce robust effects in humans (1). The drug 
preparation is described in Supplement 1.  
 
Study procedures 
 The study included a screening visit with the study physician, a separate psychiatric 
interview, an additional visit with the study physician for familiarization, two 25h test sessions, 
and an end-of-study visit. The sessions were conducted in a calm laboratory environment. 
Only one research subject and one or two investigators were present during the test sessions. 
The test sessions began at 8:15 AM. A urine sample was taken to verify abstinence from 
drugs of abuse, and a urine pregnancy test was performed in women. The subjects then 
underwent baseline measurements. LSD (200µg) or placebo was administered at 9:00 AM. 
The outcome measures were repeatedly assessed for 24h. A standardized lunch and dinner 
was served at 1:30 PM and 5:30 PM, respectively. The subjects were under constant 
supervision by the study physician until 1:00 AM. Thus, the subjects were never alone during 
the first 16h after drug administration, and the investigator was in a room next to the subject 
for up to 24h. The subjects were sent home the next day at 9:30 AM. 
 
Subjective drug effects  
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 Subjective measures included scores on the 5 Dimensions of Altered States of 
Consciousness (5D-ASC) scale (28, 48), Visual Analogue Scales (VASs) (49), the Adjective 
Mood Rating Scale (AMRS) (50), and the Addiction Research Center Inventory (ARCI) (30). 
The 5D-ASC scale is designed to be used retrospectively and was administered 24 h after 
drug administration to rate the peak drug effects. The VASs were administered repeatedly up 
to 24 h to assess drug effects over time. The AMRS and ARCI were administered before and 
3, 10, and 24 h after drug administration. The procedures are described in detail in 
Supplement 1.  
 
Acoustic startle response measurement 
 The eye-blink component of the acoustic startle response was measured using an 
electromyographic startle system (EMG-SR-Lab; San Diego Instruments, San Diego, CA, 
USA) as described in detail elsewhere (35) and in Supplement 1. Briefly, the session included 
16 pulse-alone stimuli (115dB) and 32 similar pulse trials that were preceded by a 20ms 
prepulse (86dB) and an interstimulus interval (ISI) of 30, 60, 120, or 2000ms, resulting in four 
prepulse trial conditions.  
 
Cardiovascular, autonomic, adverse, and endocrine effects  
Cardiostimulant (blood pressure, heart rate), autonomic (body temperature, pupillary 
function), psychomotor performance, endocrine measures (plasma cortisol, prolactin, oxytocin, 
norepinephrine, and epinephrine), and adverse effects were measured as described in 
Supplement 1.  
 
Data analysis 
 The data were analyzed using Statistica 12 software (StatSoft, Tulsa, OK, USA). Peak 
(Emax) or peak change from baseline (∆Emax) values were determined for repeated measures. 
Data were then analyzed using repeated-measures analysis of variance (ANOVA), with drug 
(LSD vs. placebo) as the within-subjects factor. The PPI data were analyzed using repeated-
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measures ANOVA, with drug and trial condition (30, 60, 120, and 2000ms) as within-subjects 
factors, followed by direct comparisons for each trial condition. Modulatory effects of sex and 
hallucinogen experience were evaluated by including the respective between-subjects factor 
into the ANOVA. Spearman’s rank correlations were used to determine associations between 
measures. The criterion for statistical significance was p<.05. 
 
Results 
Subjective drug effects 
 Altered states of consciousness on the 5D-ASC. LSD induced pronounced alterations 
of waking consciousness (Fig. 1). LSD most strongly increased ratings of oceanic 
boundlessness (F1,15=92.3, p<.001) and visionary restructuralization (F1,15=243.5, p<.001). The 
elevated ratings for oceanic boundlessness indicated that LSD elicited a state of positively 
experienced derealization and depersonalization with predominantly increased ratings for 
“experience of unity” (F1,15=60.2, p<.001) and “blissful state” (F1,15=68.1, p<.001). Additionally, 
LSD produced marked visionary restructuralization phenomena, including increased ratings for 
“elementary and complex imagery” (F1,15=123.8, p<.001, and F1,15=55.9, p<.001, respectively), 
“audio-visual synesthesia” (F1,15=156.8, p<.001), and “changed meaning of percepts” 
(F1,15=93.3, p<.001). LSD induced only minimal “auditory alterations” (F1,15=34.5, p<.001). LSD 
also moderately increased ratings of anxious ego-dissolution (F1,15=16.1, p<.01), mostly 
attributable to significantly increased ratings for “disembodiment” (F1,15=34.4, p<.001) and 
“impaired control and cognition” (F1,15=25.3, p<.001), but not “anxiety” (F1,15=4.2, p=.06). 
Profound anxiety or panic was not experienced by any subject. However, two subjects (one 
female and one male) reacted with transient anxiety, including fear of losing control, which 
completely resolved without pharmacological intervention within 2-3h. No sex differences were 
observed in the effects of LSD on the 5D-ASC scale. 
 Psychotropic effects over time on VASs. Subjective effects on the VASs are shown in 
Fig. 2, and maximal effects are presented in supplementary Table S2. The subjective effects 
began 30-60min after LSD administration. Peak effects (any drug effects) were reported after 
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(mean±SD) 1.75±0.82h. After 5h, the subjective effects of LSD gradually subsided but lasted 
up to 12h after LSD administration. Three subjects still rated the subjective effects >50% of 
maximal possible effects at 12h. LSD produced pronounced increases in all VAS ratings, 
including “any drug effects,” “good drug effect,” “drug high,” “drug liking,” and “stimulated,” 
compared with placebo (all F1,15≥1931, all p<.001). Peak effects for “any drug effects,” “good 
drug effect,” and “drug liking” reached up to 90% of the maximal possible score. Additionally, 
LSD significantly increased ratings of “empathogenic” drug effects, including “happy,” 
“closeness,” “open”, and “trust” (all F1,15≥34, all p<.001). LSD decreased subjective 
concentration (F1,15=212.5, p<.001). LSD induced small but significant increases in “bad drug 
effect” and “fear” (F1,15=23.9, p<.001, and F1,15=13.2, p=.003, respectively) compared with 
placebo. The subjective effects of LSD did not differ between sexes. 
 AMRS. LSD significantly increased ratings of “well-being” (F1,15=8.2, p<.05), “emotional 
excitation” (F1,15=17.4, p<.001), “inactivity” (F1,15=10.8, p<.01), “introversion” (F1,15=16.9, 
p<.001), and “dreaminess” (F1,15=57.9, p<.001) compared with placebo (Fig. 3, Table S2). LSD 
did not alter ratings of “extroversion” or “anxiety.” No sex differences were observed in the 
effects of LSD on the AMRS. 
 ARCI. Subjective effects on the ARCI are presented in Table S2 and Fig. S1. LSD 
significantly increased ratings on the amphetamine group scale (F1,15=15.8, p=.001), with a 
trend toward significantly reduced ratings on the benzedrine group scale (F1,15=3.8, p=.07). 
LSD also significantly increased ratings of euphoria and drug liking on the morphine-
benzedrine group scale (F1,15=31.3, p<.001), sedation on the pentobarbital-alcohol group scale 
(F1,15=52.6, p<.001), and ratings on the LSD group scale (F1,15=24.4, p<.001), a measure of 
dysphoric and psychotomimetic changes. No sex differences were observed in the effects of 
LSD on the ARCI. 
 Investigator-rated drug effects. The investigator-rated drug effects are shown in Table 
S2 and Fig. S2. LSD increased investigator ratings of “any drug effect” (F1,15=449.7, p<.001), 
“distance from reality” (F1,15=21.7, p<.001), “happiness” (F1,15=37.4, p<.001), and “non-speech 
vocalization” (F1,15=6.9, p<.05). LSD did not significantly increase ratings for “anxiety” or 
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“paranoid thinking.” LSD did not alter the percentage of time “talking with the investigator” 
compared with placebo. 
 
Acoustic startle response 
 The effects of LSD on PPI and startle response habituation are shown in Fig. 4. The 
data from one participant were excluded because of technical reasons. The two-way ANOVA, 
with drug and prepulse trial condition as within-subject factors, revealed a significant drug × 
prepulse trial interaction (F3,42=3.0, p<.05). LSD significantly reduced PPI in the 30ms and 
60ms trial conditions (F1,14=5.5, p<.05, and F1,14=5.1, p<.05, respectively) and also tended to 
reduce PPI in the 120ms trial condition (F1,14=3.4, p=.09; Fig. 3A). LSD nonsignificantly 
increased the startle response compared with placebo (mean reaction amplitude over all 
pulse-alone trials (mean±SD): 571±321 units and 469±190 units after administration of LSD 
and placebo, respectively. The two-way ANOVA for pulse-alone trials, with drug and block 
(time) as factors, showed a significant main effect of block, indicating habituation of the startle 
response over time (F3,42=12.8, p<.001). No drug × block interaction was observed, indicating 
similar habituation of the response over time in the LSD and placebo conditions (Fig. 4B). 
Similarly, LSD did not affect %habituation compared with placebo. No associations were found 
between %PPI disruption and any subjective effect ratings assessed shortly before or after the 
startle measurement. 
 
Cardiovascular, autonomic, adverse, and endocrine effects  
Emax values and statistics are shown in Table S2. LSD significantly increased systolic 
(F1,15=23.77, p<.001) and diastolic blood pressure (F1,15=25.19, p<.001), heart rate 
(F1,15=15.27, p=.001), and body temperature compared with placebo (F1,15=11.61, p=.004; Fig. 
5). LSD significantly increased the pupil size in the dark and after a light stimulus (F1,15=22.71 
and 36.33, respectively, both p<.001; Fig. S3). LSD significantly impaired the participants’ 
ability to balance on one foot (F1,15=26.1, p=.001; Fig. S4). LSD significantly increased the 
plasma concentrations of cortisol (F1,15=198.03, p<.001), prolactin (F1,15=10.13, p<.01), 
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oxytocin (F1,15= 9.40, p<.01), and epinephrine (F1,15=8.95, p<.01;Fig. 6). LSD significantly 
increased the total acute (0-10h; F1,15=13.67, p<.01) and subacute (10-24h; F1,15=7.19, p<.05) 
adverse effects but not adverse effects at 24-72h compared with placebo. Adverse effects at 
24-72h did not differ between LSD and placebo. The frequently reported acute adverse effects 
of LSD are presented in Table S3. There were no severe acute effects. The somatic and 
endocrine effects of LSD did not differ between sexes. 
 
Discussion 
  
Subjective effects of LSD 
 LSD induced a pronounced alteration in waking consciousness, including visual 
perceptual alterations, audio-visual synesthesia, and positively experienced derealization and 
depersonalization. LSD did not induce pronounced anxiety and overall produced high ratings 
of good drug effects and low ratings of bad drug effects. LSD also increased well-being, 
happiness, closeness to others, openness, and feelings of trust, effects typically associated 
with the empathogen MDMA (ecstasy) (51). The subjective effects of LSD began 30-60min 
after administration and peaked at 1.75h but remained high for 3-5h before gradually declining. 
The acute psychological effects of LSD lasted 12h in most subjects and up to 16h in some, 
which is longer than the 6-10 or 12h reported by others (1, 16, 52). This could be attributable 
to the relatively high dose of LSD or more sensitive psychometric measures used in the 
present study. The LSD effects lasted twice as long as those of psilocybin (6h) (53, 54) and 
were longer than the effects of DMT (<1h) (18) but possibly similarly long as those of 
mescaline (17, 55). 
 In the present study, LSD produced higher scores on the 5D-ASC scale compared with 
psilocybin in a similar population of healthy subjects (54). In particular, LSD produced 30% 
higher ratings for both oceanic boundlessness (mostly blissful state), 30% higher ratings for 
anxious ego dissolution, and 63% higher ratings for visionary restructuralization (mostly 
greater audio-visual synesthesia) compared with a high dose of psilocybin (54, 56). Compared 
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with DMT and ketamine, LSD produced 50% higher ratings for both oceanic boundlessness, 
50% higher ratings for visionary restructuralization, and comparably high ratings for anxious 
ego dissolution (21, 28). LSD produced similar ratings on the AMRS for emotional excitation, 
inactivation, and dreaminess compared with high-dose psilocybin (54). Similar to LSD, mean 
group anxiety scores were not appreciably increased by psilocybin (54). On the ARCI, LSD 
increased ratings on the amphetamine group scale and morphine-benzedrine group scale, 
suggesting stimulant and euphoric subjective effects that were similar to MDMA (57). In 
contrast, LSD reduced ratings on the benzedrine group scale, suggesting reduced energy and 
focus, unlike MDMA (57). LSD had overall similar effects to psilocybin on the ARCI (58). 
Interestingly, LSD increased subjective VAS ratings for happy, open, closeness to others, and 
trust. Similarly, the investigators rated subjects as being happier after administration of LSD 
compared with placebo. Similar subjective effects are typically produced by empathogens, 
such as MDMA, but not by stimulants (29, 59). Altogether, the psychometric findings indicate 
that LSD produced stronger perceptual alterations than the doses of other psychotropic drugs 
tested so far and also MDMA-like empathogenic mood effects. Additionally, LSD increased 
plasma oxytocin levels. Oxytocin is thought to contribute to the empathogenic and prosocial 
effects of MDMA (60) and may have similar effects in the case of LSD. Although LSD and 
MDMA were not compared in the same subjects, the present findings indicate that LSD exerts 
partially MDMA-like empathogenic effects that may be associated with common serotonergic 
and/or oxytocinergic properties (51). MDMA produces weak LSD-like perceptual alterations, 
likely via similar 5-hydroxytryptamine-2A (5-HT2A) receptor stimulation (61). Pharmacologically, 
LSD acts as a direct partial agonist at serotonergic receptors (2, 62), whereas MDMA mostly 
acts as an indirect serotonergic agonist by releasing serotonin via the serotonin transporter 
(63).  
The primary safety concerns with hallucinogen research are psychological rather than 
somatic adverse effects (1). In laboratory studies that use psilocybin, ketamine, or MDMA, 
moderate anticipatory anxiety is common at the beginning of the onset of the drug’s effects 
(58, 64, 65). Acute anxiety was also infrequently reported when LSD was administered at the 
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same dose as the one used in the present study for LSD-assisted psychotherapy in patients 
with anxiety associated with life-threatening diseases (11). In the present study, LSD produced 
anxiety in two subjects, which resolved spontaneously with verbal support from the 
investigators. Anxiety was related to fear of loss of thought control, disembodiment, and loss of 
self as similarly described for psilocybin (54). Some subjects also had to be reminded of the 
transient state of the drug-induced experience. Importantly, all of the subjects had no current 
or past history of major psychiatric disorders and were well-informed about the setting, 
acquainted with and constantly supervised by the same investigator. Also of note, only half of 
the subjects in the present study were hallucinogen-naive and the other half had very limited 
prior experience with hallucinogenic drugs. We found no differences in the quality and extent 
of the response to LSD between the hallucinogen-naive and moderately experienced subjects. 
Consistent with this finding, prior experience with hallucinogenic drugs only moderately 
affected the response to psilocybin in a similar research setting (65).  
 
Sensorimotor gating of the acoustic startle response 
In line with our hypothesis, LSD disrupted PPI and therefore produced sensorimotor 
deficits similarly to those observed in schizophrenia (35-38). LSD (39-41) and other 
serotonergic hallucinogens (42-44) reduce PPI in animals. LSD also potentiated the startle 
magnitude and impaired habituation of the startle response in rats (66). Similar deficits in 
habituation were reported in schizophrenia patients (35, 37). Consistent with the preclinical 
findings, LSD reduced PPI in the present study at the 30-120ms ISI. LSD did not significantly 
alter the startle response amplitude or its habituation. Psilocybin reduced PPI at a short ISI 
(30ms), had no effect at a medium ISI (60ms), and increased PPI at long ISIs (120-2000ms), 
without changing startle reactivity or habituation (67, 68). Thus, the effects of LSD and 
psilocybin on the acoustic startle response and its modulation were quite similar. Additionally, 
the disruption of PPI induced by psilocybin in humans at a short ISI (30ms) was prevented by 
administration of a 5-HT2A receptor antagonist (69), consistent with similar preclinical studies 
of LSD (41). In contrast to the findings with LSD and psilocybin, DMT or ayahuasca had no 
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effects on PPI, startle reactivity, or habituation in humans (19, 70). Altogether, the effects of 
LSD on PPI in normal humans were consistent with both the PPI deficits after LSD 
administration in animals and sensorimotor gating deficits in schizophrenia patients.  
Serotonergic hallucinogens, including LSD, are hypothesized to act at the 5-HT2A 
receptor (2, 53), which is upregulated in schizophrenia patients (71). Prepulse inhibition is 
influenced by genetic variations in the 5-HT2A receptor gene (72), and PPI deficits induced by 
psilocybin in humans depend on 5-HT2A receptor stimulation (69). In animals, LSD disrupts 
PPI (39-41) also via 5-HT2A receptor stimulation (41). To further characterize the role of 5-HT2 
receptors and other receptors in the subjective and sensorimotor psychotomimetic effects of 
LSD in humans, further studies should investigate the effects of receptor antagonists on the 
response to LSD using a similar experimental setting. The present findings lend support to the 
use of LSD to study the neurobiological basis of psychotic states in humans. To date, brain 
activation patterns have not yet been studied using LSD in neuroimaging studies, in contrast to 
several modern investigations that used psilocybin to model psychotic states (24, 25).  
 
Autonomic and endocrine effects 
LSD produced significant sympathomimetic effects including increases in blood 
pressure, heart rate, and pupil size. Similar findings were reported in early studies in the 1950s 
(73-77). In contrast, LSD (200µg, orally) did not alter diastolic or systolic blood pressure or 
heart rate in a recent study in eight patients with different chronic life-threatening illnesses 
(11). Overall, the cardiostimulant effects of LSD were moderate and smaller than those seen 
with empathogens and stimulants (29). The LSD-induced increase in epinephrine levels in the 
present study was similar to the effect produced by MDMA (78).  
LSD increased body temperature in the present study. LSD is thermogenic in animals 
(79) and hyperthermia has been reported to be a consequence of massive LSD overdose in 
humans (80). Other serotonergic hallucinogens including psilocybin and DMT produce similar 
cardiostimulant and autonomic responses to LSD (17, 54, 58, 81-83).  
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LSD increased circulating levels of cortisol and prolactin in the present study. LSD 
binds to dopaminergic D2 receptors (84). LSD inhibited prolactin secretion by rat pituitary cells 
(85) and decreased plasma levels of prolactin in rats (86). This led to the suggestion that LSD 
acts as a dopamine D2 receptor agonist in the pituitary. However, the present study in humans 
found that LSD increased the plasma levels of prolactin and cortisol, which are both markers 
of serotonergic activity (87, 88). Our findings suggest that the serotonergic stimulant effects of 
LSD on prolactin regulation usurp any dopamine D2 receptor-mediated inhibition in humans at 
the dose used in the present study. Other serotonergic drugs, including psilocybin (54), DMT 
(83), ayahuasca (89), and MDMA (29, 90), increased the plasma levels of both prolactin and 
cortisol in humans.  
 
The present study has several limitations. First, we only used a single dose of LSD, 
and we cannot provide dose-response data. We used a relatively high dose of LSD (200µg), 
which clearly produced a full and representative LSD response (1). The same dose of LSD 
was also recently used in patients with anxiety associated with terminal illness (11). Second, 
although we used formal blinding, the overt subjective effects of LSD unblinded the treatment 
assignment. Additionally, expectations may have influenced the psychological effects of LSD 
because all of the subjects knew that they would receive LSD or placebo and not another 
active drug. Furthermore, the psychological effects and risks of LSD are likely to be different 
from those described herein if LSD is used recreationally in unsupervised settings or in 
subjects with psychiatric disorders. Third, endocrine measures were performed only at two 
time-points during the expected peak drug effect, thus not allowing for a full characterization of 
the endocrine effects of LSD over a longer time interval. 
 
In conclusion, LSD produced marked effects on perception but also subjective effects 
on mood that were similar to those reported for MDMA and increased plasma oxytocin, 
suggesting empathogenic properties that may be useful in psychotherapy (11). LSD acutely 
decreased PPI of the acoustic startle response, consistent with preclinical data and the 
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sensorimotor deficits seen in schizophrenia. The present experimental human study may 
serve as an interface for the translation of preclinical research with hallucinogens to clinical 
research findings in patients with schizophrenia and vice versa. LSD may be useful for further 
studying alterations in consciousness and information processing in humans. The present 
study showed that LSD can be safely administered in an experimental research setting in 
humans, thus forming a basis for further psychopharmacological studies. However, the 
sympathomimetic stimulant effects need to be considered when LSD is to be used in patients 
with hypertension or heart disease. 
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FIGURE LEGENDS 
 
 
Figure 1. Effects of LSD on the Altered States of Consciousness (5D-ASC) scale. LSD 
predominantly increased ratings of oceanic boundlessness (OB) and visionary 
restructuralization (VR). Increased OB ratings mostly resulted from higher ratings for blissful 
state and experience of unity. Increases in VR ratings were attributable to high ratings for 
audio-visual synesthesia, elementary and complex imagery, and changed meaning of 
percepts. LSD produced only very little auditory alterations (AA). LSD-induced increases in 
anxious ego-dissolution (AED) were small because of elevated ratings for disembodiment, 
impaired control, and cognition but not anxiety. Vigilance (VIR) was significantly reduced by 
LSD compared with placebo. The global ASC score consists of the summation of the OB, 
AED, and VR scores. **p<.01, ***p<.001, compared with placebo. The data are expressed as 
the mean ± SEM in 16 subjects.  
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Figure 2. Subjective effects of LSD over time on the Visual Analogue Scales (VASs). LSD or 
placebo was administered at t=0. The subjective effects began 30-60min after LSD 
administration, peaked after 1-5h, gradually subsided after 5h, and were increased up to 12h. 
LSD produced significant changes in all VAS ratings. However, “bad drug effects” and “fear” 
were only minimally elevated. LSD also increased ratings that are typically increased by 
empathogens, including ratings for “happy,” “closeness,” “open,” and “trust.” The data are 
expressed as the mean ± SEM % maximal values in 16 subjects. 
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 Figure 3. Subjective effects on the Adjective Mood Rating Scale (AMRS). LSD or placebo 
was administered at t = 0. LSD induced increases in general well-being (A), emotional 
excitation (B), inactivity (C), introversion (D), and dreaminess (F). LSD did not induce 
significant anxiety (E). The data are expressed as the mean ± SEM change from baseline in 
16 subjects. *p < .05, **p < .01, ***p < .001, compared with placebo. 
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Figure 4. Effects of LSD on the percentage of prepulse inhibition (%PPI) of the acoustic startle 
response (A) and startle response habituation over time (B). LSD significantly reduced %PPI 
in trials with prepulses that were presented 30 or 60ms before the startle pulse compared with 
placebo (A). A trend toward a significant reduction of %PPI was observed for the 120ms 
prepulse trial condition. LSD did not significantly alter the startle response or startle response 
habituation compared with placebo (B). The data are expressed as the mean ± SEM in 15 
subjects. *p<.05, (*)p=.09, compared with placebo.  
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Figure 5. Effect of LSD on vital signs. LSD or placebo was administered at t = 0 h. LSD 
significantly increased systolic (A) and diastolic (B) blood pressure, heart rate (C), and body 
temperature (D) compared with placebo. Comparisons for each time point revealed that the 
cardiostimulant (A, B) and thermogenic (D) changes induced by LSD were significant up to 5 h 
after drug administration compared with placebo, but moderate trend changes remained up to 
11 h before the levels returned to baseline. The data are expressed as the mean ± SEM in 16 
subjects. *p<.05, **p<0.01, ***p < .001, compared with placebo. 
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Figure 6. Endocrine effects of LSD. LSD significantly increased the plasma concentrations of 
prolactin (A), cortisol (B), oxytocin (C), and epinephrine (D). LSD did not significantly alter the 
plasma levels of norepinephrine (E). LSD or placebo was administered at t = 0min. The data 
are expressed as the mean ± SEM in 16 subjects. **p<.01, ***p<.001, compared with placebo. 
 
 
